Last reviewed · How we verify
XIAFLEX
Xiaflex is a collagenase that breaks down collagen in fibrotic tissue, allowing mechanical manipulation to improve joint mobility and function.
Xiaflex is a collagenase that breaks down collagen in fibrotic tissue, allowing mechanical manipulation to improve joint mobility and function. Used for Dupuytren's contracture with palpable cord.
At a glance
| Generic name | XIAFLEX |
|---|---|
| Also known as | Collagenase, collagenase clostridium histolyticum |
| Sponsor | Hospital for Special Surgery, New York |
| Drug class | Collagenase enzyme |
| Target | Collagen (types I, II, III, IV, V, VI, VII) |
| Modality | Biologic |
| Therapeutic area | Orthopedics / Rheumatology |
| Phase | FDA-approved |
Mechanism of action
Xiaflex contains clostridial collagenase, an enzyme that cleaves collagen in pathological fibrotic cords. By enzymatically degrading the collagen matrix of Dupuytren's contracture cords, the drug weakens the tissue structure, enabling subsequent manual manipulation by a healthcare provider to straighten the affected fingers. This minimally invasive approach avoids surgical excision while achieving similar functional outcomes.
Approved indications
- Dupuytren's contracture with palpable cord
Common side effects
- Injection site reactions (pain, swelling, bruising)
- Lymphadenopathy
- Tendon rupture
- Nerve injury
- Allergic reaction
Key clinical trials
- Safety and Efficacy of Collagenase Clostridium Histolyticum After Prior Intralesional PRP for Peyronie's Disease (PHASE4)
- Concurrent Low Intensity Shockwave Therapy on Collagenase Clostridium Histolyticum for Peyronie's Disease (NA)
- A Study to Assess Collagenase Clostridium Histolyticum (CCH) in the Treatment of Plantar Fasciitis (PFA) (PHASE2)
- Fasciectomy vs Collagenase Injection in Recurrent Dupuytren Disease (PHASE4)
- Trial Comparing Treatment Strategies in Dupuytren's Contracture (PHASE4)
- Study of Different Interventions to Reduce Bruising Following CCH-Aaes Treatment for Cellulite of the Buttocks (PHASE2)
- Effectiveness of Splinting After Collagenase Injection (PHASE3)
- Delayed Dose Collagenase Clostridium Histolyticum (CCH) Protocol for Men With Peyronie's Disease (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- XIAFLEX CI brief — competitive landscape report
- XIAFLEX updates RSS · CI watch RSS
- Hospital for Special Surgery, New York portfolio CI